Agilent and BioNanomatrix to Develop Genetic Analysis System Using Nanoscale Whole Genome Imaging Technology
News Nov 06, 2007
BioNanomatrix will apply its nanoscale single molecule imaging technology to develop consumable chips and reagents, while Agilent will develop the measurement instrumentation platform for the system.
"This collaboration with Agilent provides us with the opportunity to join forces with a global life sciences leader to accelerate the development of our unique nanoscale whole genome imaging technology," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix.
"We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life-sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing," he said.
BioNanomatrix is developing technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format.
The company's patented analytic platform based on this technology has the potential to provide ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.
Further details of the agreement were not disclosed.
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE
Mouse Model Demonstrates Potential of New Autism DrugNews
Scientists have performed a successful test of a possible new drug in a mouse model of an autism disorder. The candidate drug, largely corrected electrical, behavioral and brain abnormalities in the mice.READ MORE